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Purpose
The present analysis of pooled data from those 3 trials
was performed to characterize the efficacy and adverse
events of topiramate for migraine prevention in subjects
who had used other migraine preventive medications.
Metods
We were analyzed patients with migraine, who had used
migraine preventive medications, within approximately 8
months period.Patients were admitted to the Depart-
ment of Neurology in Nis, after observing their mia-
graine atack, during the period from January-December
2013.All of the patients have been diagnostically exam-
end by:interictal EEG, head CT, MRI,MRA angiography.
We analyzed monthly migraine frequency from baseline
period to endpoint. We compared different dosage of
topiramate, so as the presence od adverse events.We
started with 25mg/day od topiramate and this lasted for
7 days and we incresed dosage of topiramate 25 mg/
week. Maximum dosage was 200 mg/day.
Results
Of sum of 167 patients, 96 (57,48%)female, aged between
21-59 years (mean age 39, 2) were recruited. Subjects were
treated with topiramate(50, 100 or 200 mg/day). More
subjects on topiramate 50 mg./day (41%), 100 mg./day
(63%) and 200 mg./day (54%) exhibited ≥ 50% reductions
in monthly migraine frequency. Most common adverse
event was paresthesis, incidence was 11%, fatigue 3%, nau-
sea 2%. Mean duration of paresthesia was 19 days. Cogni-
tive sympthoms was registered only in 2 patients.
Conclusion
In subjects who had previously taken other migraine
preventives, treatment with topiramate100 mg/day and
200 mg/day significantly reduced mean monthly
migraine frequency. In our study, the lower dose of
topiramate exhibited similar efficacy. Adverse events is
rarely and most frequent is paresthesia which
disappeares in 3 weeks.
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